All News

RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
PSA2L.jpg

Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib

d Jack Cush, MD

Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.

Read Article
lupus,nephritis,GN

Could Anifrolumab Work in Lupus Nephritis?

d Jack Cush, MD

Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.

Read Article
Kawasaki.jpg

Kawasaki Disease Guideline from ACR and Vasculitis Foundation

d ACR

The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of

Read Article
pills,combo,push,blister

Combo MTX and Leflunomide in Psoriatic Arthritis

d Jack Cush, MD

A recent study has shown that the combination of methotrexate (MTX) plus leflunomide (LEF) yields better disease control in psoriatic arthritis, but may not be as well tolerated as monotherapy with MTX.

Read Article
ICYMI: Undifferentiated Arthritis Does Not Follow an RA Course UA is common in medical practice and many advocate early use of DMARDs; yet a recent study shows that despite DMARD use, UA patients do not fair well with this approach. https://t.co/l0U4IVAXMG https://t.co/8YPM8DgX8H

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/tg5eETiMO4 https://t.co/bC45AAnP3h

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is Coming to Town! Have you signed up for RheumNow Live yet? We still have space available. It kicks off one week from today! https://t.co/mMlAC3OXTJ https://t.co/DY32PxQnRm https://t.co/kcIQ2GdObr

Links:

Dr. John Cush RheumNow ( View Tweet)
The Differential on Tenosynovitis 70 yr old man with tenosynovitis - imagine the possibilities QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/HraAZHIKA9 https://t.co/nzG6tlXuJU

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe. https://t.co/XYK02MRMp6 https://t.co/LgToS5NCaa

Links:

Dr. John Cush RheumNow ( View Tweet)
Could Anifrolumab Work in Lupus Nephritis? Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit. https://t.co/6EtLf1nhv6 https://t.co/RrJX08vcIK

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 177 PsA pts, those with dactylitis had more severe disease with signif. greater SJC, CRP, US-detected synovitis and bone erosions in DMARD-naive early PsA. Dactylitis could be useful in early risk stratification. https://t.co/zUoWSEFxaN

Links:

Dr. John Cush RheumNow ( View Tweet)

6780 nonspecific MSK pts (no synovitis) saw 3% w/ CCP+, 45% progressed to IA (RA). Progression seen w/ high CCP (OR 9.4), hand (OR 2.7) & foot pain (OR 4.1). CCP- progress if pain in hands (OR 2.5) or knees. 96% NPV for CCP- w/o hand/foot pain https://t.co/FbDIggQFLJ https://t.co/VtvRUOHTnc

Links:

Dr. John Cush RheumNow ( View Tweet)
What To Do With the NSAID? Elderly arthritis needs something for pain - what to do with the NSAID? QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/YmGTOVJymm https://t.co/T3Y8LUNHVk

Links:

Dr. John Cush RheumNow ( View Tweet)
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/Idlqidy04d https://t.co/su3PI5fSaS

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC reports no cross-reactivity of serologic tests performance between Dengue, Zika and SARS-CoV-2 EIA. Study of febrile patients in Puerto Rico (DENV is endemic) with confirmed SARS-CoV-2, DENV, or Zika Dx. EIA specificity was ≥98% https://t.co/nXEBMuSDZL https://t.co/fa9yOqtxiI

Links:

Dr. John Cush RheumNow ( View Tweet)
Changing to a new biologic or sticking with the old one - a PsA patient chooses QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/VJ5tuLN6ae https://t.co/OrxVBwNUsx

Links:

Dr. John Cush RheumNow ( View Tweet)
Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial https://t.co/PcQC6sQWyu https://t.co/Dqsq6BneM9

Links:

Dr. John Cush RheumNow ( View Tweet)
Failed Osteoarthritis Pulse Ultrasound Study https://t.co/6JpiVBOfuV https://t.co/3F4iRVZjUs

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center study of individualized anakinra use in 47 autoinflammatory pts (32kids; 43% MAS; 40% systemic JIA). Off-label use in 38%, higher doses in 21 kids (5-29mg/kg); & 5 given IV anakinra; such doses were well tolerated without major AE. https://t.co/wQgw3YAPKX https://t.co/zL3HfdX4Ns

Links:

Dr. John Cush RheumNow ( View Tweet)
×